Outcomes by baseline alpha-fetoprotein (AFP) levels in the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in previously treated advanced hepatocellular carcinoma (HCC) Meeting Abstract
| Authors: | Kelley, R. K.; El-Khoueiry, A. B.; Meyer, T.; Rimassa, L.; Merle, P.; Chan, S. L.; Tran, A.; Parnis, F.; Tam, V. C.; Cattan, S.; Markby, D. W.; Clary, D. O.; Cheng, A. L.; Abou-Alfa, G. K. |
| Abstract Title: | Outcomes by baseline alpha-fetoprotein (AFP) levels in the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in previously treated advanced hepatocellular carcinoma (HCC) |
| Meeting Title: | 43rd ESMO Congress (ESMO 2018) |
| Journal Title: | Annals of Oncology |
| Volume: | 29 |
| Issue: | Suppl. 8 |
| Meeting Dates: | 2018 Oct 19-23 |
| Meeting Location: | Munich, Germany |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2018-10-01 |
| Start Page: | mdy282.085 |
| Language: | English |
| ACCESSION: | WOS:000459277301281 |
| PROVIDER: | wos |
| DOI: | 10.1093/annonc/mdy282.085 |
| Notes: | Meeting Abstract: 702P -- Appears on page viii236 of the abstract book -- Source: Wos |
